Omicron sublineage recombinant XBB evades neutralising antibodies in recipients of BNT162b2 or CoronaVac vaccines

Zhang, Xiaojuan; Chen, Lin-Lei; Ip, Jonathan Daniel; Chan, Wan-Mui; Hung, Ivan; Yuen, Kwok‐Yung; Li, Xin; To, Kelvin Kai‐Wang

doi:10.1016/s2666-5247(22)00335-4

Cited by 40 publications

(37 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We and other groups have shown that XBB has higher immune-evasion capabilities than earlier variants, including BA.5 and BA.2. 1 , 2 , 3 , 4 , 5 Although XBB.1.5 and XBB share most of the amino acid substitutions in the receptor-binding domain of the spike protein, which is the major target for vaccines and therapeutic monoclonal antibodies against SARS-CoV-2, XBB.1.5 has an additional substitution not found in XBB (ie, S486P). Therefore, we should evaluate the efficacy of therapeutic drugs and the effect of COVID-19 vaccines against XBB.1.5.…”

mentioning

confidence: 99%

Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate

Uraki

Ito

Kiso

et al. 2023

The Lancet Infectious Diseases

View full text Add to dashboard Cite

mentioning

confidence: 99%

Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate

Uraki

Ito

Kiso

et al. 2023

The Lancet Infectious Diseases

View full text Add to dashboard Cite

“…One of the most commonly applied mRNA vaccine delivery approaches is that of encapsulating mRNA molecules in lipid nanoparticles (LNP). Their high entrapment efficiency protects mRNA from degradation, while the ease of fusion of liposomes with recipient cells improves the efficiency of mRNA delivery ( Zhan Zhang et al, 2022 ). The efficiency of using LNP as the delivery system for siRNA has been demonstrated since 2006; however, its application as the in vivo delivery tool for mRNA molecules has only been considered in recent years.…”

Section: Summary Of Different Types Of Available Vaccine Platformsmentioning

confidence: 99%

An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines

Bayani

Hashkavaei

Arjmand

et al. 2023

Progress in Biophysics and Molecular Biology

View full text Add to dashboard Cite

“…XBB is a recombinant of the BA.2.10.1 and BA.2.75 sublineages which was first documented on samples collected on 13 August 2022 [4] , with early evidence of an association with a higher risk of reinfection [2] . A recent study concluded that XBB evades neutralizing antibodies in recipients of BNT162b2 or CoronaVac vaccines [5] . XBB.1.5, a sublineage of XBB with an additional spike mutation (S486P) in the receptor binding domain, is currently estimated to have a large expansion advantage and is of considerable concern due to its rapid spread in December 2022.…”

mentioning

confidence: 99%